Kerna Laboratories Raises Funding to Advance AI-Driven mRNA Therapeutics
Founded just nine months ago, Kerna Laboratories combines cutting-edge AI with biotechnology to address the challenges of mRNA payload design.
Company Name: Kerna Laboratories
Location: San Francisco, CA
Industry: AI Biotechnology
Funding Details:
Amount: Undisclosed
Investors: Gradient, Humba Ventures, Tau Ventures, Pioneer Fund, Focalpoint Partners, Patrick Hsu (Arc Institute), Jacob Kimmel (NewLimit)
Purpose of Investment:
The funds will support Kerna Laboratories in expanding operations and advancing its development efforts.
Leadership:
- Amit Deshwar: Co-Founder (ex-SVP, Deep Genomics)
- Melissa J. Moore: Co-Founder (ex-CSO, Moderna)
- Julia Peng: CEO and Co-Founder
- Michael Swift: Founding Scientist and Co-Founder
About the Company:
Kerna Laboratories combines cutting-edge AI with biotechnology to address the challenges of mRNA payload design. The company’s mission is to unlock new therapeutic possibilities by innovating the next generation of mRNA therapies, leveraging advanced computational and scientific methodologies.
Focus:
- mRNA Payload Design: Applying AI to overcome obstacles in designing effective mRNA therapeutics.
- Therapeutic Innovation: Driving the development of new therapies to expand the impact of mRNA in medicine.
With its latest funding and an experienced leadership team, Kerna Laboratories is poised to redefine mRNA therapeutic design and accelerate breakthroughs in biotechnology.
